reports
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recu...
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A preliminary analysis of recurrence rates by two methods...
Greenwich LifeSciences Announces Completion of Enrollment in the Open ...
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned...
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
Universal Technical Institute Inc: 1 director
A director at Universal Technical Institute Inc bought 547,066 shares at 25.011USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- Jonathan Moreland
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screenin...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its scr...
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Cl...
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Austria. The Company's application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in addition to ...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 C...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich ...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical O...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SBH SALLY BEAUTY HOLDINGS INC.
RYAM RAYONIER ADVANCED MATERIALS INC
PSX PHILLIPS 66
LPSN LIVEPERSON INC.
LLY ELI LILLY AND COMPANY
KURA KURA ONCOLOGY INC.
ICUI ICU MEDICAL INC.
CROX CROCS INC.
ASA ASA
KODK EASTMAN KODAK CO
AAOI APPLIED OPTOELECTRONICS INC.
ADC AGREE REALTY CORPORATION
PETS PETMED EXPRESS INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
SGU STAR GROUP L.P.
UA UNDER ARMOUR
BHC INC.
ESTA BAUSCH HEALTH COMPANIES INC.
AMPY ESTABLISHMENT LABS HOLDINGS
PRKA AMPLIFY ENERGY
DLHC PARKS! AMERICA INC
PRCT DALEIGH HOLDINGS CORP
TSE PROCEPT BIOROBOTICS CORP
NRGV TRINSEO PLC
MSDL ENERGY VAULT HOLDINGS INC
INSG MORGAN STANLEY DIRECT LENDING
FINS INSEEGO CORP.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate E...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
NG. NOVAGOLD RESOURCES INC.
WELL WELLTOWER INC.
CDXS CODEXIS
CDTX CIDARA THERAPEUTICS
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
DOMO BRIDGEWATER BANCSHARES
SONO DOMO INCORPORATED
A2JHXF SONOS
FGBI CEVA LOGISTICS AG
PVH FIRST GUARANTY BANCSHARES
AMPY PHILLIPS-VAN HEUSEN CORPORATION
INLX AMPLIFY ENERGY
FRHC INTELLINETICS
RZLT INC.
KYMR FREEDOM HOLDING CORP
WSC REZOLUTE
BTBT INC.
TERN KYMERA THERAPEUTICS
NUVB WILLSCOT MOBILE MINI HOLDINGS CORP
CTO BIT DIGITAL (N SHARES)
VERA TERNS PHARMACEUTICALS
IMRX NUVATION BIO INC (A)
XLO CONSOLIDATED-TOMOKA LAND CO
SSBK VERA THERAPEUTICS INC
NCDL IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU NUVEEN CHURCHILL DIRECT LENDING CORP
SUNS PERFECT MOMENT LTD.
MBRX NEW YORK CITY REIT
HYMC INC.
THAR ACTUATE THERAPEUTICS INC.
FGEN SUNRISE REALTY TRUST
CCIF MOLECULIN BIOTECH INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
MTH MERITAGE HOMES CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
CDXS CODEXIS
CABO CABLE ONE INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
ADC AGREE REALTY CORPORATION
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
TTI TETRA TECHNOLOGIES INC.
VRA VERA BRADLEY INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
BHC BRIDGEWATER BANCSHARES
DOMO BAUSCH HEALTH COMPANIES INC.
SONO DOMO INCORPORATED
BLDR SONOS
AMPY BUILDERS FIRSTSOURCE
INLX INC.
DCTH AMPLIFY ENERGY
RZLT INTELLINETICS
WSC INC.
GRNT DELCATH SYSTEMS
TERN REZOLUTE
NUVB INC.
CTO WILLSCOT MOBILE MINI HOLDINGS CORP
VERA GRANIT SKOPKE
IMRX TERNS PHARMACEUTICALS
XLO NUVATION BIO INC (A)
SSBK CONSOLIDATED-TOMOKA LAND CO
GECC VERA THERAPEUTICS INC
BARK IMMUNEERING CORP
MNR XILIO THERAPEUTICS INC
NCDL SOUTHERN STATES BANCSHARES INC
SUNS GREAT ELM CAPITAL CORP
MBRX ORIGINAL BARK CO
WHLR MACH NATURAL RESOURCES LP
HYMC NUVEEN CHURCHILL DIRECT LENDING CORP
THAR SUNRISE REALTY TRUST
RVYL MOLECULIN BIOTECH INC.
INUV WHEELER REAL ESTATE INVESTMENT TRUST INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
RYVYL INC.
INUVO INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.